Proteostasis withdraws stock offering due to market conditions
Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion
Global M&A by the Numbers: Q2 2022
Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms
Infographic 2022 Top Tech Trends Shaping Corporations
Proteostasis Therapeutics Inc. withdrew its previously announced underwritten public offering of 9 million common shares.
The Cambridge, Mass.-based biopharma company said "current market conditions are not conducive for an offering."